Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Emerging drugs for the treatment of myelofibrosis.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Quality of life in MPN comes of age as a therapeutic target.